Home/Nanexa AB/Cecilia Danckwardt-Lillieström
CD

Cecilia Danckwardt-Lillieström

Chief Financial Officer (CFO)

Nanexa AB

Therapeutic Areas

Nanexa AB Pipeline

DrugIndicationPhase
NEX-20Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML)Phase I
NEX-18Oncology (Multiple Myeloma)Preclinical
NEX-22Type 2 Diabetes / ObesityDiscovery/Preclinical